Aziz Kabeer 4
4 · AN2 Therapeutics, Inc. · Filed Jan 18, 2024
Insider Transaction Report
Form 4
Aziz Kabeer
Director
Transactions
- Sale
Common Stock
2024-01-16$19.65/sh−84,093$1,652,427→ 1,995,958 total(indirect: By Adjuvant Global Health Technology Fund, L.P.) - Sale
Common Stock
2024-01-16$19.65/sh−15,907$312,573→ 377,542 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
Footnotes (2)
- [F1]Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
- [F2]Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.